Eddine Saiah

Company: Stablix

Job title: Chief Scientific Officer

Seminars:

Harnessing Deubiquitinases (DUBs) as a Novel Therapeutic Modality 8:30 am

Identifying high impact targets for targeted deubiquitination therapeutics (TDT) Deploying novel ligands for DUB recruitment Novel insights into TDT and RESTORAC developmentRead more

day: Post-Conference Focus Day: Next Generation TPD